Skip to main content
U.S. flag
Health and Human Services Logo

An official website of the Department of Health & Human Services

menu-iconMore mobile-close-icon
mobile-back-btn-icon Back
  • menu-iconMenu
  • mobile-search-icon
AHRQ: Agency for Healthcare Research and Quality
  • Search All AHRQ Sites
  • Careers
  • Contact Us
  • Español
  • FAQs
  • Email Updates
MEPS Home Medical Expenditure Panel Survey
Font Size:
Contact MEPS FAQ Site Map  
S
M
L
XL
 

STATISTICAL BRIEF #66:
Top 10 Outpatient Prescription Medicines Ranked by Utilization and Expenditures for the Elderly in the U.S. Community Population, 2002


February 2005
Marie N. Stagnitti, MPA

Highlights

  • Expenditures for prescribed medicines reported as purchased by the elderly in the U.S. community population totaled $49.9 billion in 2002, an increase of 12.6 percent from the $44.3 billion total reported in 2001, and an increase of 116 percent from the $23.1 billion total reported in 1996.
  • In 2002, when ranked by total expenditures, the top 10 prescribed medicines totaled $12.4 billion, representing nearly one-fourth (24.8 percent) of total prescribed medicine expenditures by the elderly.
  • Three cholesterol-lowering medicines, Lipitor, Zocor, and Pravachol, ranked first, second, and third in terms of total expenditures for prescribed medicines by the elderly in 2002 ($2.5 billion, $2.3 billion, and $1.1 billion, respectively).
  • Lipitor ranked first for the elderly in terms of total expenditures ($2.5 billion) and total number of purchases (26.48 million) in 2002.
  • In 2002, five antihypertensive medicines, Hydrochlorothiazide, Furosemide, Atenolol, Toprol, and Norvasc, made the 2002 top 10 when ranked by total purchases and totaled 105.51 million prescriptions, which represented 11.5 percent of all prescriptions purchased by the elderly.

Introduction


This Statistical Brief provides a summary of the top 10 outpatient prescription medicines for persons age 65 and older (elderly) in the U.S. civilian noninstitutionalized (community) population by utilization and expenditures, as reported by household respondents in calendar year 2002. The brief also provides trends in annual prescribed medicine expenditures by the elderly from 1996 to 2002.

The estimates in this brief are derived from prescribed medicine data in the Household Component of the 2002 Medical Expenditure Panel Survey (MEPS-HC). Over-the-counter medicines and free samples are not included in these estimates. All results discussed are statistically significant at the 0.05 level.

Findings


In 2002, the top 10 household-reported prescribed medicines for the elderly when ranked by annual expenditures totaled $12.4 billion. This represented nearly a quarter (24.8 percent) of the $49.9 billion total spent by the elderly on prescription medicines in 2002 (figure 1) and included the following:

Top 10 Prescribed Medicines for Persons Age 65 and Older, by Total Expenditures, 2002
Rank
Prescribed medicine name
Total dollars (in billions)
1
Lipitor
$2.47
2
Zocor
$2.28
3
Pravachol
$1.13
4
Prilosec
$1.04
5
Norvasc
$1.02
6
Plavix
$1.00
7
Fosamax
$0.91
8
Prevacid
$0.89
9
Celebrex
$0.87
10
Atenolol
$0.83
Total
Total of top 10
$12.44


In 2002, the top three prescribed medicines for the elderly in terms of expenditures were all cholesterol-lowering medicines. Lipitor ranked first at $2.47 billion, Zocor ranked second at $2.28 billion, and Pravachol ranked third at $1.13 billion. These three medicines alone totaled $5.9 billion, and represented 11.8 percent of total prescription medicine expenditures by the elderly in 2002.

Ranking fourth and eighth in 2002 total prescription medicine expenditures for the elderly were two anti-ulcer medicines, Prilosec and Prevacid. Prilosec ranked fourth, with a total of $1.04 billion, and Prevacid eighth, with $0.89 billion. The total expenditures for these two medicines combined were $1.9 billion and represented 3.8 percent of total prescription medicine expenditures by the elderly in 2002.

Norvasc and Atenolol, two antihypertensive medicines, ranked fifth and tenth, with expenditures of $1.02 billion and $0.83 billion, respectively. The total for these two prescribed medicines was $1.9 billion and represented 3.8 percent of total prescription medicine expenditures by the elderly in 2002.

Plavix, a platelet aggregation inhibitor, ranked sixth in total prescription medicine expenditures by the elderly in 2002, with $1.00 billion. Fosamax, a bone resorption inhibitor, ranked seventh with $0.91 billion. Celebrex, a Cox-2 inhibitor non-steroidal anti-inflammatory, ranked ninth with $0.87 billion.

In 2002, the top 10 household-reported prescribed medicines for the elderly when ranked by total annual utilization totaled 195.83 million prescriptions. This represented 21.3 percent of the 919.03 million total prescription medicines purchased by the elderly in 2002 (data not shown) and included the following:

Top 10 Prescribed Medicines for Persons Age 65 and Older, by Total Utilization, 2002
Rank
Prescribed medicine name
Total utilization (in millions of prescriptions)
1
Lipitor
26.48
2
Hydrochlorothiazide
22.61
3
Furosemide
21.96
4
Atenolol
21.93
5
Toprol
21.41
6
Synthroid
19.76
7
Zocor
17.92
8
Norvasc
17.60
9
Premarin
13.74
10
Fosamax
12.42
Total
Total of top 10
195.83


Lipitor ranked first in terms of utilization by the elderly with a total of 26.48 million prescriptions purchased in 2002. Zocor ranked seventh in terms of total number of prescriptions purchased with 17.92 million prescriptions. The utilization for these two cholesterol-lowering medicines combined totaled 44.40 million prescriptions, which represented 4.8 percent of total prescribed medicine purchases by the elderly in 2002.

In 2002, antihypertensive medicines ranked second, third, fourth, fifth, and eighth in terms of number of prescriptions purchased by the elderly. These medicines were Hydrochlorothiazide (22.61 million), Furosemide (21.96 million), Atenolol (21.93 million), Toprol (21.41 million) and Norvasc (17.6 million), respectively. The combined total for these antihypertensive medicines totaled 105.51 million prescriptions and represented 11.5 percent of the total prescriptions purchased by the elderly in 2002.

Synthroid, a thyroid medicine, was sixth when ranked by total purchases, with 19.76 million prescriptions purchased by the elderly in 2002.

Rounding out the top 10 prescriptions purchased by the elderly in 2002 were Premarin and Fosamax in the ninth and tenth spots. Premarin, an estrogen, was ninth with 13.74 million prescriptions, and Fosamax, a bone resorption inhibitor, was tenth with 12.42 million prescriptions purchased.

Data Source


The estimates in this Statistical Brief are drawn from analyses using the 1996-2002 MEPS prescribed medicines public use files: HC-010A, HC-016A, HC-026A, HC-033A, HC-051A, HC-059A, and HC-067A.

About MEPS-HC


MEPS-HC is a nationally representative longitudinal survey that collects detailed information on health care utilization and expenditures, health insurance, and health status, as well as a wide variety of social, demographic, and economic characteristics for the civilian noninstitutionalized population. It is cosponsored by the Agency for Healthcare Research and Quality and the National Center for Health Statistics.

For more information about MEPS, call the MEPS information coordinator at AHRQ (301-427-1406) or visit the MEPS Web site at http://www.meps.ahrq.gov/.

References


For a detailed description of the MEPS-HC survey design, sample design, and methods used to minimize sources on nonsampling error, see the following publications:

Cohen, J. Design and Methods of the Medical Expenditure Panel Survey Household Component. MEPS Methodology Report No. 1. AHCPR Pub. No. 97-0026. Rockville, Md.: Agency for Health Care Policy and Research, 1997.

Cohen, S. Sample Design of the 1996 Medical Expenditure Panel Survey Household Component. MEPS Methodology Report No. 2. AHCPR Pub. No. 97-0027. Rockville, Md.: Agency for Health Care Policy and Research, 1997.

Suggested Citation


Stagnitti, M. N. Top 10 Outpatient Prescription Medicines Ranked by Utilization and Expenditures for the Elderly in the U.S. Community Population, 2002. Statistical Brief #66. February 2005. Agency for Healthcare Research and Quality, Rockville, MD. http://meps.ahrq.gov/mepsweb/data_files/publications/st66/stat66.shtml
Table containing figure values follows image.
Figure 1. Total prescription drug expenditures for the U.S. civilian noninstitutionalized population age 65 and older (elderly), 1996-2002
1996199719981999200020012002
Billions of dollars23.124.127.132.633.844.349.9
Source: Center for Financing, Access, and Cost Trends, AHRQ, Household Component of the Medical Expenditure Panel Survey, 2002

MEPS HOME . CONTACT MEPS . MEPS FAQ . MEPS SITE MAP . MEPS PRIVACY POLICY . ACCESSIBILITY . VIEWERS & PLAYERS . COPYRIGHT
Back to topGo back to top
Back to Top Go back to top

Connect With Us

Facebook Twitter You Tube LinkedIn

Sign up for Email Updates

To sign up for updates or to access your subscriber preferences, please enter your email address below.

Agency for Healthcare Research and Quality

5600 Fishers Lane
Rockville, MD 20857
Telephone: (301) 427-1364

  • Careers
  • Contact Us
  • Español
  • FAQs
  • Accessibility
  • Disclaimers
  • EEO
  • Electronic Policies
  • FOIA
  • HHS Digital Strategy
  • HHS Nondiscrimination Notice
  • Inspector General
  • Plain Writing Act
  • Privacy Policy
  • Viewers & Players
  • U.S. Department of Health & Human Services
  • The White House
  • USA.gov